title: [Prevalence of metabolic syndrome in patients with stable coronary disease: therapeutic objectives and utilization of cardiovascular drugs].
abstract: OBJECTIVE
  The achievement of the therapeutic objectives in patients with ischemic heart disease and metabolic syndrome is unknown. This study has aimed to evaluate whether the prevalence of risk factors, the prescription rate of evidence-based cardiovascular therapies and the attainment of therapeutic goals differ in coronary patients with and without the metabolic syndrome (MS).
  
  
  METHODS
  A multicenter, cross-sectional study carried out with the participation of 7,600 patients with stable coronary heart disease (mean age 65.3 years, 82% males, 37.7% with MS) attended in primary care. Data on drug prescription and goal attainment were extracted from clinical records. MS was defined according to the National Cholesterol Education Program (NCEP) criteria.
  
  
  RESULTS
  Patients with MS had a higher prevalence of cardiovascular risk factors and cardiovascular disease. They also had a higher prescription rate of blood-pressure lowering drugs, statins and antidiabetic agents, without differences in the rate of use of antithrombotics and beta-blockers. After adjusting for cardiovascular risk factors and co-morbidity, only fibrates and angiotensin II receptor blockers were used more frequently in MS patients. A lower percentage of subjects with MS achieved therapeutic goals of LDL cholesterol (23.4% vs 27.7%, P<.001), blood pressure (29.1% vs 52.2%, P<.001) and, in diabetics, of glycated hemoglobin (54.7% vs 75.9%, P<.001).
  
  
  CONCLUSIONS
  Patients with stable coronary disease and MS do not reach therapeutic objectives as frequently as those without MS, in spite of receiving a higher amount of cardiovascular drugs.
authors.affiliation: Unidad de Arteriosclerosis, Hospital Carlos III, Madrid, España. clahoz.hciii@salud.madrid.org
authors.forename: C
authors.initials: C
authors.lastname: Lahoz
authors.forename: J M
authors.initials: JM
authors.lastname: Mostaza
authors.forename: M T
authors.initials: MT
authors.lastname: Mantilla
authors.forename: M
authors.initials: M
authors.lastname: Taboada
authors.forename: S
authors.initials: S
authors.lastname: Tranche
authors.forename: I
authors.initials: I
authors.lastname: López-Rodríguez
authors.forename: B
authors.initials: B
authors.lastname: Monteiro
authors.forename: M A
authors.initials: MA
authors.lastname: Sánchez-Zamorano
authors.forename: R
authors.initials: R
authors.lastname: Martín-Jadraque
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D003327:Coronary Disease / Q000150:complications* / Q000188:drug therapy*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000453:epidemiology*; D015995:Prevalence; D012307:Risk Factors
chemical_list: D002317:Cardiovascular Agents